171 related articles for article (PubMed ID: 37163498)
1. Inhibition of ERK signaling for treatment of ERRα positive TNBC.
Musheyev D; Miller E; Birnbaum N; Miller E; Erblich S; Schuck A; Alayev A
PLoS One; 2023; 18(5):e0283047. PubMed ID: 37163498
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
3. Inverse agonist of estrogen-related receptor α suppresses the growth of triple negative breast cancer cells through ROS generation and interaction with multiple cell signaling pathways.
Wu YM; Chen ZJ; Jiang GM; Zhang KS; Liu Q; Liang SW; Zhou Y; Huang HB; Du J; Wang HS
Oncotarget; 2016 Mar; 7(11):12568-81. PubMed ID: 26871469
[TBL] [Abstract][Full Text] [Related]
4. A novel compound LingH2-10 inhibits the growth of triple negative breast cancer cells in vitro and in vivo as a selective inverse agonist of estrogen-related receptor α.
Ning Y; Chen H; Du Y; Ling H; Zhang L; Chen L; Qi H; Shi X; Li Q
Biomed Pharmacother; 2017 Sep; 93():913-922. PubMed ID: 28715872
[TBL] [Abstract][Full Text] [Related]
5. ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer.
Manna S; Bostner J; Sun Y; Miller LD; Alayev A; Schwartz NS; Lager E; Fornander T; Nordenskjöld B; Yu JJ; Stål O; Holz MK
Clin Cancer Res; 2016 Mar; 22(6):1421-31. PubMed ID: 26542058
[TBL] [Abstract][Full Text] [Related]
6. Advances in Medicinal Chemistry of Estrogen-related Receptor Alpha (ERRα) Inverse Agonists.
Zhang H; Du Y; Zheng Y; Lv H; Yan Z; Dong N; Zhu Y; Shen J
Curr Top Med Chem; 2023; 23(20):1952-1963. PubMed ID: 37190810
[TBL] [Abstract][Full Text] [Related]
7. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
[TBL] [Abstract][Full Text] [Related]
8. The discovery of a novel series of potential ERRα inverse agonists based on p-nitrobenzenesulfonamide template for triple-negative breast cancer
Gao Z; Wang T; Li R; Du Y; Lv H; Zhang L; Chen H; Shi X; Li Q; Shen J
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):125-134. PubMed ID: 34894977
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a selective inverse agonist for estrogen related receptor α as a potential agent for breast cancer.
Zhang L; Liu P; Chen H; Li Q; Chen L; Qi H; Shi X; Du Y
Eur J Pharmacol; 2016 Oct; 789():439-448. PubMed ID: 27498368
[TBL] [Abstract][Full Text] [Related]
10. Estrogen-Related Receptor Alpha (ERRα) Promotes Cancer Stem Cell-Like Characteristics in Breast Cancer.
Muduli K; Prusty M; Pradhan J; Samal AP; Sahu B; Roy DS; Reddy KS; Elangovan S
Stem Cell Rev Rep; 2023 Nov; 19(8):2807-2819. PubMed ID: 37584854
[TBL] [Abstract][Full Text] [Related]
11. Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1.
Li Y; Birnbaumer L; Teng CT
Mol Endocrinol; 2010 May; 24(5):969-80. PubMed ID: 20211987
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol as an Endogenous Ligand of ERRα Promotes ERRα-Mediated Cellular Proliferation and Metabolic Target Gene Expression in Breast Cancer Cells.
Ghanbari F; Mader S; Philip A
Cells; 2020 Jul; 9(8):. PubMed ID: 32717915
[TBL] [Abstract][Full Text] [Related]
13. Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.
Thewes V; Simon R; Schroeter P; Schlotter M; Anzeneder T; Büttner R; Benes V; Sauter G; Burwinkel B; Nicholson RI; Sinn HP; Schneeweiss A; Deuschle U; Zapatka M; Heck S; Lichter P
Cancer Res; 2015 Feb; 75(4):720-31. PubMed ID: 25643697
[TBL] [Abstract][Full Text] [Related]
14. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells.
Sulaiman A; McGarry S; Lam KM; El-Sahli S; Chambers J; Kaczmarek S; Li L; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Liu S; Xie Y; Gadde S; Li X; Wang L
Cell Death Dis; 2018 Jul; 9(8):815. PubMed ID: 30050079
[TBL] [Abstract][Full Text] [Related]
15. The discovery of novel, potent ERR-alpha inverse agonists for the treatment of triple negative breast cancer.
Du Y; Song L; Zhang L; Ling H; Zhang Y; Chen H; Qi H; Shi X; Li Q
Eur J Med Chem; 2017 Aug; 136():457-467. PubMed ID: 28525844
[TBL] [Abstract][Full Text] [Related]
16. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
[TBL] [Abstract][Full Text] [Related]
17. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
18. IL-8 Is Involved in Estrogen-Related Receptor α-Regulated Proliferation and Migration of Colorectal Cancer Cells.
Ding S; Tang Z; Jiang Y; Huang H; Luo P; Qing B; Zhang S; Tang R
Dig Dis Sci; 2017 Dec; 62(12):3438-3446. PubMed ID: 28993941
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen suppresses brain metastasis of estrogen receptor-deficient breast cancer by skewing microglia polarization and enhancing their immune functions.
Wu SY; Sharma S; Wu K; Tyagi A; Zhao D; Deshpande RP; Watabe K
Breast Cancer Res; 2021 Mar; 23(1):35. PubMed ID: 33736709
[TBL] [Abstract][Full Text] [Related]
20. Estrogen-Related Receptor α (ERRα) and G Protein-Coupled Estrogen Receptor (GPER) Synergistically Indicate Poor Prognosis in Patients with Triple-Negative Breast Cancer.
Ye S; Xu Y; Wang L; Zhou K; He J; Lu J; Huang Q; Sun P; Wang T
Onco Targets Ther; 2020; 13():8887-8899. PubMed ID: 33061416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
